EGFR and head and neck squamous cell carcinoma: Since its approval, the epidermal growth factor receptor (EGFR) antibody cetuximab, in combination with RT, has been increasingly used to treat patients with HNSCC, especially when platinum-based chemotherapy is contraindicated because of toxicity [7], in the elderly, or in addition to cisplatin or anti-PD1 in recurrent disease.